Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: sjemmeri who wrote (4522)	12/7/2005 11:25:30 AM
From: keokalani'nui	Respond to of 4974

Clarus Ventures closes inaugural fund at $500M Tuesday December 6, 5:06 pm ET Early-stage investor Clarus Ventures has closed its inaugural investment fund with $500 million in capital commitments. The Cambridge-based venture firm said it plans to support biotechnology and pharmaceutical companies by deploying its money in $20 million to $30 million increments, with a maximum investment size of $50 million per company. Clarus said it will likely commence its investment strategy in early 2006. Deals will involve companies in myriad stages of development, and will include opportunities in both privately and publicly held companies. The firm said it will also look overseas at potential investments in European-based life sciences companies. In addition to its main office in Cambridge, Clarus also manages an office in San Francisco. The company's investment team is comprised of veterans from a handful of branded life-sciences firms and venture outfits, including Millennium Pharmaceuticals in Cambridge, Genentech Inc. in San Francisco, Venrock Associates in Cambridge and Mayfield Fund in Menlo Park, Calif. Published December 6, 2005 by the Boston Business Journal